CLAIMS

1. A composition comprising:

a) Rapamycin;

b) Monolaurin and Monomyristin as vehicle; and

c) water;

for use in the treatment of a vascular abnormality of the skin of a human subject by topically administering the composition to the abnormality once daily at a rate of:

d) 4-8 mg Rapamycin /cm^2; and/or

e) 1-6 mg Rapamycin;

wherein the vascular abnormality comprises:

f) angiofibroma;

g) cutaneous vascular lesion; or

h) port wine stain.

2. A composition according to claim 1, for use in treating the vascular abnormality once daily at a rate of:

a) 5 - 7 mg Rapamycin /cm^2; and/or

b) 2-5 mg Rapamycin.

3. A composition according to claim 1, for use in treating the vascular abnormality once daily at a rate of:

a) about 6 mg Rapamycin /cm^2; and/or

b) 3-4 mg Rapamycin.

4. A composition according to claim 1, 2 or 3, for use in treating the vascular abnormality for at least 1, 2, 3, 4, 5 or 6 months.

5. A composition according to any one of claims 1-4, for use in treating the vascular abnormality for at least 1, 2, 3, 4, 5, or 6 months such that the concentration of the Rapamycin in the bloodstream of the subject, if any, does not exceed 1, 2, 3, 4 or 5 ng/mL.

6. A composition according to any one of claims 1-4, for use in treating the vascular abnormality for at least 1, 2, 3, 4, 5, or 6 months of such that the concentration of the Rapamycin in the bloodstream of the subject, if any, does not exceed 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9 ng/mL.

7. A composition according to any one of the preceding claims, comprising 0.5 - 5% wt Rapamycin.

8. A composition according to claim 7, comprising approximately 0.5% Rapamycin.

9. A composition according to claim 7, comprising approximately 1% Rapamycin.

10. A composition according to any one of the preceding claims, comprising monolaurin at approximately 7 - 28% wt, or approximately 5% - 10% wt, or approximately 7% wt.

11. A composition according to any one of the preceding claims, comprising monomyristin at approximately 7%-28% wt or approximately 15%-25% wt, or approximately 21% wt.

12. A composition according to any one of the preceding claims, comprising:

a) 5% - 9% wt Monolaurin + 19% – 23% wt Monomyristin; or

b) 12% - 16% wt Monolaurin + 12 - 16% wt Monomyristin.

13. A composition according to any one of the preceding claims, comprising:

a) about 7% wt Monolaurin + about 21% wt Monomyristin; or

b) about 14% wt Monolaurin + about 14% wt Monomyristin.

14. A composition according to any one of the preceding claims, comprising one or more of a water retainer, a softener, a buffer, a sequestrant, hydroxide for pH adjustment, and a preservative.

15. A composition according to any one of claims 1-7, comprising 0.5 – 5% wt Rapamycin, 17.5% (±2%) wt Monolaurin and 10.5% (±2%) wt Monomyristin.

16. A composition according to any one of claims 1-7, comprising 0.5% or 1% wt Rapamycin, 21% wt Monolaurin and 7% wt Monomyristin.

17. A composition according to any one of the preceding claims, wherein the Monolaurin is glyceryl monolaurate and the Monomyristin is glyceryl monomyristate.

18. A composition according to any one of claims 1-7, comprising:

a) 0.5 – 5% wt Rapamycin;
b) vehicle comprising:
    - 10-18% wt monolaurin; and
    - 10-18% wt monomyristin; and
c) water as a solvent.

19. The use of:

a) Rapamycin;
b) Monolaurin and Monomyristin as vehicle; and
c) water;

for the manufacture of a medicament composition for treating a vascular abnormality of the skin of a human subject by topically administering to the abnormality the composition once daily at a rate of:

d) 4 -8 mg Rapamycin /cm^2; and/or
e) 1-6 mg Rapamycin;

wherein the vascular abnormality comprises:

f) angiofibroma;
g) cutaneous vascular lesion; or
h) port wine stain.

20. A composition comprising:

a) Rapamycin as active ingredient;
b) vehicle comprising monolaurin and monomyristin, and
c) water as a solvent;

for use in the treatment of a vascular abnormality comprising angiofibroma, a cutaneous vascular lesion or a port wine stain, on the skin of a human subject, by topically applying

the composition to the abnormality, once daily for at least 1, 2, 3, 4, 5, or 6 months, such that at the conclusion of the at least 1, 2, 3, 4, 5, 6 months the concentration of the rapamycin in the bloodstream of the subject, if any, does not exceed 1, 2, 3, 4 or 5 ng/mL.